8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 16, 2026)

Filed April 16, 2026For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report on April 16, 2026, to announce its financial results for the first quarter of 2026. The filing primarily directs investors to a furnished press release (Exhibit 99.1) which contains the detailed financial performance and operational updates for the period. While specific GAAP figures are not detailed in the 8-K text itself, the company emphasizes its use of non-GAAP financial measures. These adjusted figures exclude items such as acquisition-related expenses, stock-based compensation acceleration, restructuring costs, certain regulatory costs, and tax adjustments, aiming to provide a clearer view of ongoing business performance. Management believes these non-GAAP measures offer valuable insights into operational trends, complementing the standard GAAP reporting.

Key Highlights

  • 1Abbott Laboratories (ABT) reported its Q1 2026 financial results on April 16, 2026.
  • 2The 8-K filing references a press release (Exhibit 99.1) containing the detailed financial results.
  • 3The company utilizes non-GAAP financial measures to present its results, alongside GAAP figures.
  • 4Non-GAAP measures exclude specific items like acquisition expenses, stock-based compensation acceleration, and restructuring costs.
  • 5Abbott's management uses non-GAAP measures to assess and communicate ongoing business performance.
  • 6Investors are advised to consider non-GAAP measures in addition to, not as a substitute for, GAAP financial measures.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and provide access to Abbott Laboratories' financial results for the first quarter of 2026.

The detailed Q1 2026 financial results are provided in the press release (Exhibit 99.1) that is furnished with this 8-K filing. Investors should refer to this press release for specific financial data.

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) figures. Abbott uses them to provide investors with a clearer view of the company's ongoing operational performance by adjusting for unusual or unpredictable items like acquisition-related costs, restructuring actions, and certain tax adjustments.

Abbott's management believes these non-GAAP measures offer useful insights into business performance. However, the company advises investors to consider these non-GAAP measures in conjunction with, and not as a replacement for, the financial measures prepared in accordance with GAAP.